NSCLC Molecular Reports: Preparing a Treatment Review in Shanghai

Start with the confirmed cancer and its stage

Confirm that the pathology diagnosis is non-small cell lung cancer, or NSCLC, and record its subtype and stage. This discussion does not apply directly to small-cell lung cancer or an undiagnosed pulmonary nodule. Ask whether the proposed decision concerns treatment before or after surgery, locally advanced disease or cancer that has spread or returned. Molecular information has to be interpreted within that setting; a report listing a possible drug does not establish that it is appropriate at every stage. Bring the staging examinations and pathology report rather than relying on a gene-test cover sheet.

Sources and references: [1] [2]

Keep the full result and the test method together

Provide every page of the laboratory report, including the exact alteration, specimen type, collection date, testing method and any quality or interpretation notes. Gene names such as EGFR or ALK are only the beginning of the discussion. Ask what specific finding was detected, whether the relevant type of alteration was assessed and whether a separate protein-based test is needed for the treatment question. Tests differ in what they look for; a small panel, a broad panel and a protein test should not be treated as interchangeable simply because all are called biomarker testing.

Sources and references: [1] [2]

Ask whether the sample can answer the question

Testing may use tissue obtained during biopsy or surgery, or a blood sample in selected circumstances. A tissue sample may be insufficient, and obtaining another biopsy may carry risks that must be balanced against the information expected. A report without an actionable finding is not a guarantee that every potentially relevant marker has been excluded. Ask the team whether the sample, test coverage and quality support that interpretation, and whether further testing would change management. Do not arrange an invasive repeat procedure or ship tissue until the receiving hospital specifies what is needed and how it should be handled.

Sources and references: [2]

Separate a useful result from an uncertain one

A detected change may support a treatment choice, suggest that a treatment is unlikely to help, or have no established practical use. A variant of uncertain significance should not be treated as proof that a targeted drug will work. Even a biomarker that matches a recognised treatment does not guarantee benefit: other cancer features and differences among tumour cells can affect response. Ask the oncologist to distinguish an established clinical use from a hypothesis or research option and to explain the expected benefits, adverse effects and monitoring of any proposed treatment.

Sources and references: [2]

Interpret the report at the right point in treatment

A report describes the sample at the time it was collected. Cancer biology can change, so an older result may not answer a question arising after treatment or recurrence. Build a timeline of therapies, dates, dose changes, responses and side effects, including why each treatment stopped. If disease has progressed, ask whether reviewing stored tissue, testing a new specimen or another assessment would be useful. Repeat testing is a clinical decision, not an automatic requirement. While requesting a second opinion, discuss any proposed interruption or change in current medication with the treating oncologist.

Sources and references: [1] [2]

Choose resources that match the clinical question

Shanghai lung-cancer specialists can help turn a gene name on a report into a concrete treatment decision. Shanghai Pulmonary Hospital, Tongji University has experience in thoracic diagnosis, imaging and lung-tumour care, and Shanghai Chest Hospital has research and clinical work in molecularly defined lung cancer. Bring the complete pathology, staging scans, testing method and treatment history to examine which findings change your current options, whether another test would help and how medicines fit with other care. Our Lung cancer guide helps you prepare; eastmedgo can match your case with an appropriate Shanghai lung-cancer team.

Sources and references: [3] [4]

Check practical access and cost before making travel plans

A report may cite a treatment approval or trial from another country. That does not establish a Chinese indication, supply, reimbursement or current recruitment. Ask the hospital to verify the intended use, clinical eligibility and practical access, with the alternative plan if the option is unavailable. Request separate estimates for consultation, pathology review, tissue handling, additional testing and treatment monitoring. Explain whether follow-up would occur in Shanghai or at home. The cost of a test and the cost of the treatment it might suggest are separate decisions and should be budgeted separately.

Sources and references: [1] [2] [4]

Request an answer that can guide the next clinician

The written review should connect the diagnosis, stage, sample and precise result to the recommended next step. It should identify unresolved questions, explain any proposed additional test and state who will check the result. If treatment changes, ask for monitoring and side-effect instructions that the home team can use. Seek prompt local care for significant deterioration during this process rather than allowing a pending overseas report to delay assessment. eastmedgo can organise the records needed for interpreting molecular findings alongside pathology, stage and earlier medicines, match you with Shanghai specialists and coordinate bilingual communication and return-home handover. To see how coordination works, read about eastmedgo's services or contact us with your records.

Sources and references: [1] [2]

Common questions